Effect and Prognosis of Immunohistochemical Biomarkers Changes in Patients With Bladder Cancer After Neoadjuvant Chemotherapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University60 enrolled

Overview

Clinical trial to investigate the relationship between the expression of immunohistochemical biomarkers GATA-3, CK20, P53 and Ki67 in bladder cancer and pathological complete response after neoadjuvant chemotherapy.

This is a retrospective study included bladder cancer patients treated with neoadjuvant chemotherapy. We analyzed the changes in the expression of GATA-3, CK20, P53 and Ki67 before and after NAC. Evaluating the sensitivity factor for predicting pathological complete response.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bladder Cancer

Interventions

neoadjuvant chemotherapyOTHER

The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Any male or female patient aged 18 or older. 2. Histologically confirmed bladder cancer, cystectomy was performed after NAC. 3. Complete clinical data. Exclusion Criteria: 1. Patients with severe organic disease who can not tolerate chemotherapy or surgery 2. Patients received previous treatment (chemotherapy, radiation, or molecular targeted therapy). 3. Patients with distant metastasis or other cancer history.

Outcomes

Primary Outcomes

Expression of immunohistochemical biomarkers GATA-3, CK20, P53 and Ki67

Time frame: 1 year

Tumor regression grade

Time frame: 1 year

Central Contacts

Hao Chen

CONTACT

+86-02034078960 chenh585@mail2.sysu.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.